- -

Charlotte K F Neuerburg1, Friederike Schmitz1, Marie-Therese Schmitz2

  • 1Department of Oncology, Hematology, Immuno-Oncology and Rheumatology, University Hospital Bonn, Bonn, Germany; Center for Integrated Oncology (CIO) ABCD, Aachen Bonn Cologne Düsseldorf, Germany.

PubMed
概括

在异质造血干细胞移植 (allo-HSCT) 期间停止抗生素预防,显示出非劣质的结果,生存率和移植对宿主疾病 (GvHD) 率相似. 密切监测对于没有预防性抗生素接受alo-HSCT的患者至关重要.